$AKTX to advance lead candidate Coversin into Phase 3

Akari Therapeutics (AKTX) had an End-of-Phase 2 meeting with the FDA and announced that they will advance lead candidate Coversin into Phase 3 development for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Q1 2018. 

Shares are up 6% in pre-market.

Read detail in our SeekingAlpha Marketplace Daily Pharma Scoop.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *